A detailed history of Creative Planning transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Creative Planning holds 73,489 shares of IOVA stock, worth $628,330. This represents 0.0% of its overall portfolio holdings.

Number of Shares
73,489
Previous 71,593 2.65%
Holding current value
$628,330
Previous $574,000 20.21%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$7.28 - $11.9 $13,802 - $22,562
1,896 Added 2.65%
73,489 $690,000
Q2 2024

Aug 15, 2024

SELL
$7.78 - $14.19 $42,556 - $77,619
-5,470 Reduced 7.1%
71,593 $574,000
Q1 2024

May 10, 2024

BUY
$7.59 - $17.47 $306,370 - $705,176
40,365 Added 109.99%
77,063 $1.14 Million
Q4 2023

Feb 14, 2024

BUY
$3.3 - $8.89 $70,728 - $190,539
21,433 Added 140.41%
36,698 $298,000
Q3 2023

Nov 16, 2023

BUY
$4.44 - $8.79 $67,776 - $134,179
15,265 New
15,265 $69,000
Q2 2021

Aug 04, 2021

SELL
$16.33 - $33.07 $107,026 - $216,740
-6,554 Closed
0 $0
Q1 2021

Apr 30, 2021

BUY
$28.67 - $52.59 $60,923 - $111,753
2,125 Added 47.98%
6,554 $207,000
Q4 2020

Jan 29, 2021

BUY
$28.04 - $50.26 $124,189 - $222,601
4,429 New
4,429 $206,000
Q2 2019

Jul 26, 2019

SELL
$9.78 - $24.52 $195,600 - $490,400
-20,000 Closed
0 $0
Q3 2018

Oct 25, 2018

BUY
$11.25 - $17.7 $3,937 - $6,195
350 Added 1.78%
20,000 $225,000
Q2 2018

Jul 20, 2018

BUY
$12.45 - $16.95 $101,405 - $138,057
8,145 Added 70.8%
19,650 $252,000
Q1 2018

Apr 18, 2018

BUY
$8.1 - $19.5 $93,190 - $224,347
11,505 New
11,505 $194,000

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.35B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.